These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23741448)

  • 1. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
    Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
    PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
    Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China.
    Shen J; Ji C; Luo X; Hu Y
    PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
    Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
    Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.